Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. (Nasdaq: RVMD) generates frequent news as a late-stage clinical oncology company advancing a pipeline of RAS(ON) inhibitors for RAS-addicted cancers. Its public announcements highlight clinical trial milestones, regulatory designations and corporate developments related to drug candidates such as daraxonrasib, elironrasib and zoldonrasib.
News coverage for RVMD often centers on clinical data readouts and trial progress. The company has reported results from studies of daraxonrasib in metastatic pancreatic ductal adenocarcinoma (PDAC) in both previously treated and first-line settings, as well as combination regimens with gemcitabine and nab-paclitaxel. It also releases updates on global Phase 3 trials, including RASolute 302 and 304 in PDAC and RASolve 301 in RAS-mutant non-small cell lung cancer (NSCLC).
Another key news theme is regulatory interaction with the U.S. Food and Drug Administration. Revolution Medicines has announced FDA Breakthrough Therapy Designations for daraxonrasib, elironrasib and zoldonrasib in specific KRAS-mutant NSCLC and pancreatic cancer settings, Orphan Drug Designation for daraxonrasib in pancreatic cancer, and a Commissioner’s National Priority Voucher for daraxonrasib. These items are frequently covered in press releases and investor communications.
Investors and observers can also expect corporate and financial updates, including quarterly financial results, strategic financing transactions such as the Royalty Purchase Agreement with Royalty Pharma, and leadership appointments to support late-stage development and potential commercialization. Conference presentations at major healthcare and oncology meetings, where the company shares updated clinical and preclinical data, are another recurring source of news.
This news page aggregates such disclosures, offering a centralized view of Revolution Medicines’ clinical progress, regulatory milestones and corporate events for those tracking RVMD’s development in RAS-driven oncology.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will present significant preclinical data at the AACR Annual Meeting 2023, taking place from April 14-19, 2023, in Orlando, Florida. Notable presentations include the discovery of RMC-6291, a tri-complex KRAS G12C inhibitor, and RMC-9805, a first-in-class mutant-selective KRAS G12D inhibitor that synergizes with immunotherapy in preclinical models. These innovations aim to address RAS-addicted cancers, showcasing the company's commitment to developing targeted oncological therapies. The presentations are scheduled for April 16 and 17, highlighting advancements in cancer treatment that could significantly impact future clinical strategies.
Revolution Medicines, Inc. (Nasdaq: RVMD) has successfully closed an underwritten public offering, raising $345 million by selling 15,681,818 shares of common stock at a price of $22.00 per share. The underwriters fully exercised their option to purchase additional shares, contributing 2,045,454 shares to the total. The offering was managed by J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities. The registration statement was filed on March 2, 2021, and this transaction is crucial for funding the company's research and development of targeted therapies for RAS-addicted cancers.
Revolution Medicines has announced a public offering of 13,636,364 shares of common stock at $22.00 each, aiming to raise approximately $300 million. All shares are offered by the company, with an additional option for underwriters to purchase up to 2,045,454 shares within 30 days. The offering is expected to close on March 7, 2023. J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities are the joint book-running managers. The funds will support ongoing developments in targeted therapies for RAS-addicted cancers, part of Revolution Medicines' R&D pipeline.
Revolution Medicines, Inc. (Nasdaq: RVMD) has initiated an underwritten public offering to sell up to $300 million of its common stock. The offering includes a 30-day option for underwriters to purchase an additional $45 million worth of shares. The offering is subject to market conditions and might not be completed as proposed. J.P. Morgan, TD Cowen, SVB Securities, and Guggenheim Securities are the joint book-running managers for this offering. The company focuses on developing targeted therapies for RAS-addicted cancers, with a robust R&D pipeline centered on RAS(ON) and Companion Inhibitors.
Revolution Medicines (RVMD) reported Q4 2022 financial results, revealing total revenue of $15.3 million versus $9.5 million YoY, primarily from collaboration with Sanofi. This increase was partly due to a non-cash $7.6 million revenue adjustment following the termination of the Sanofi agreement. R&D expenses surged to $66.1 million, reflecting higher clinical trial costs for new drugs RMC-6236 and RMC-6291. The company recorded a net loss of $56.5 million for the quarter. Looking ahead, RVMD anticipates a net loss of $335 to $365 million for 2023. Its pipeline includes several promising RAS(ON) Inhibitors with clinical advancements expected in 2023.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced it will report its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. Senior management will discuss these results and corporate progress during a webcast at 4:30 p.m. Eastern Time. The company is focused on developing targeted therapies for RAS-addicted cancers, with key products in clinical development, including RMC-6236 and RMC-6291. The webcast will also be available as an archived session on its website for at least 14 days.
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology firm, announced its participation in two upcoming investor conferences. CEO Mark A. Goldsmith will speak at the Guggenheim Healthcare Talks 2023 Oncology Conference on February 9, 2023, at 9:00 a.m. Eastern, and at the SVB Securities Global Biopharma Conference on February 16, 2023, at 1:00 p.m. Eastern. The Guggenheim event will take place in-person at the St. Regis New York, while the SVB conference will be virtual. Live webcasts will be accessible through the company’s website, with replays available for 14 days post-conferences.
Revolution Medicines, a clinical-stage oncology firm focusing on targeted therapies for RAS-addicted cancers, announced that CEO Mark A. Goldsmith will present at the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. Goldsmith's presentation is scheduled for January 10 at 11:15 a.m. Pacific in the Georgian Room of the Westin St. Francis Hotel. Live access to the presentation will be available on the company's website, and a replay will be accessible for at least 14 days post-conference.
Revolution Medicines (Nasdaq: RVMD) announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing RMC-5552, a bi-steric mTORC1-selective inhibitor. This compound exhibits a remarkable 40-fold selectivity for mTORC1 over mTORC2. Preclinical studies revealed that RMC-5552, in combination with a KRASG12C inhibitor, led to tumor regressions in resistant non-small cell lung cancer models. Phase 1/1b trials for RMC-5552 in patients with refractory solid tumors are ongoing, with promising initial antitumor activity reported.
Revolution Medicines, Inc. (Nasdaq: RVMD) announced the termination of its collaboration with Sanofi for the development of RMC-4630, a SHP2 inhibitor for RAS-addicted cancers. This decision allows Revolution Medicines to regain full control over the drug’s development and commercialization strategies. The transition is expected to occur in the first half of 2023. The company will continue its Phase 2 study of RMC-4630 in combination with sotorasib, providing topline data by late 2023. The projected 2022 GAAP net loss is updated to $245-265 million.